India
· Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 296.46 billion. The enterprise value is 340.24 billion.
| Market Cap | 296.46B |
| Enterprise Value | 340.24B |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Piramal Pharma has 1.33 billion shares outstanding. The number of shares has increased by 8.30% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | +8.30% |
| Shares Change (QoQ) | -7.69% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 22.87% |
| Float | 607.58M |
Valuation Ratios
The trailing PE ratio is 762.12 and the forward PE ratio is 127.78. Piramal Pharma's PEG ratio is 1.70.
| PE Ratio | 762.12 |
| Forward PE | 127.78 |
| PS Ratio | 3.31 |
| PB Ratio | 3.75 |
| P/TBV Ratio | 7.95 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.70 |
Enterprise Valuation
| EV / Earnings | 874.66 |
| EV / Sales | 3.80 |
| EV / EBITDA | 23.03 |
| EV / EBIT | 47.44 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 3.40 |
| Debt / FCF | n/a |
| Interest Coverage | 1.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 3.24% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 13.32M |
| Profits Per Employee | 57,896 |
| Employee Count | 6,719 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.52% in the last 52 weeks. The beta is 0.10, so Piramal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +56.52% |
| 50-Day Moving Average | 212.50 |
| 200-Day Moving Average | 220.54 |
| Relative Strength Index (RSI) | 57.28 |
| Average Volume (20 Days) | 9,276,757 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 89.49 billion and earned 389.00 million in profits. Earnings per share was 0.29.
| Revenue | 89.49B |
| Gross Profit | 53.51B |
| Operating Income | 6.48B |
| Pretax Income | 3.69B |
| Net Income | 389.00M |
| EBITDA | 13.71B |
| EBIT | 6.48B |
| Earnings Per Share (EPS) | 0.29 |
Balance Sheet
The company has 4.08 billion in cash and 47.86 billion in debt, giving a net cash position of -43.78 billion or -33.02 per share.
| Cash & Cash Equivalents | 4.08B |
| Total Debt | 47.86B |
| Net Cash | -43.78B |
| Net Cash Per Share | -33.02 |
| Equity (Book Value) | 79.07B |
| Book Value Per Share | 59.51 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 59.79%, with operating and profit margins of 7.25% and 0.43%.
| Gross Margin | 59.79% |
| Operating Margin | 7.25% |
| Pretax Margin | 4.13% |
| Profit Margin | 0.43% |
| EBITDA Margin | 15.32% |
| EBIT Margin | 7.25% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 0.05%.
| Dividend Per Share | 0.11 |
| Dividend Yield | 0.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -8.30% |
| Shareholder Yield | -8.25% |
| Earnings Yield | 0.13% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |